MA27134A1 - Derives diarylcycloalkyle, leur procede de preparation et leur utilisation en tant qu'activateurs des ppar - Google Patents

Derives diarylcycloalkyle, leur procede de preparation et leur utilisation en tant qu'activateurs des ppar

Info

Publication number
MA27134A1
MA27134A1 MA27527A MA27527A MA27134A1 MA 27134 A1 MA27134 A1 MA 27134A1 MA 27527 A MA27527 A MA 27527A MA 27527 A MA27527 A MA 27527A MA 27134 A1 MA27134 A1 MA 27134A1
Authority
MA
Morocco
Prior art keywords
preparation process
derivatives
ppar activators
diarylcycloalkyl
diarylcycloalkyl derivatives
Prior art date
Application number
MA27527A
Other languages
English (en)
Inventor
Heiner Glombik
Eugen Falk
Wendelin Frick
Stefanie Keil
Hans-Ludwing Schafer
Lothar Schwink
Wolfgang Wendle
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10142734A external-priority patent/DE10142734A1/de
Priority claimed from DE2002123273 external-priority patent/DE10223273A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MA27134A1 publication Critical patent/MA27134A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA27527A 2001-08-31 2004-02-11 Derives diarylcycloalkyle, leur procede de preparation et leur utilisation en tant qu'activateurs des ppar MA27134A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10142734A DE10142734A1 (de) 2001-08-31 2001-08-31 Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE2002123273 DE10223273A1 (de) 2002-05-24 2002-05-24 Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
MA27134A1 true MA27134A1 (fr) 2005-01-03

Family

ID=26010044

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27527A MA27134A1 (fr) 2001-08-31 2004-02-11 Derives diarylcycloalkyle, leur procede de preparation et leur utilisation en tant qu'activateurs des ppar

Country Status (36)

Country Link
US (1) US6624185B2 (fr)
EP (1) EP1425014B1 (fr)
JP (1) JP4436129B2 (fr)
KR (1) KR100915108B1 (fr)
CN (1) CN1255103C (fr)
AR (1) AR039063A1 (fr)
AT (1) ATE347890T1 (fr)
AU (1) AU2002333456B2 (fr)
BG (1) BG108598A (fr)
BR (1) BR0212158A (fr)
CA (1) CA2458210C (fr)
CO (1) CO5560562A2 (fr)
CR (1) CR7261A (fr)
CY (1) CY1106378T1 (fr)
DE (1) DE50208960D1 (fr)
DK (1) DK1425014T3 (fr)
EE (1) EE05418B1 (fr)
ES (1) ES2278077T3 (fr)
HK (1) HK1067560A1 (fr)
HR (1) HRP20040199A2 (fr)
HU (1) HUP0401564A3 (fr)
IL (2) IL160556A0 (fr)
MA (1) MA27134A1 (fr)
MX (1) MXPA04001850A (fr)
MY (1) MY132789A (fr)
NZ (1) NZ531440A (fr)
OA (1) OA12656A (fr)
PE (1) PE20030414A1 (fr)
PL (1) PL208515B1 (fr)
PT (1) PT1425014E (fr)
RS (1) RS50889B (fr)
RU (1) RU2330846C2 (fr)
TN (1) TNSN04039A1 (fr)
TW (1) TWI305724B (fr)
UA (1) UA76773C2 (fr)
WO (1) WO2003020269A1 (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1238347C (zh) * 2000-05-26 2006-01-25 日本新药株式会社 杂环衍生物
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
US6884812B2 (en) * 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
US7078404B2 (en) * 2002-04-11 2006-07-18 Sanofi-Aventis Deutschland Gmbh Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
US7049341B2 (en) * 2002-06-07 2006-05-23 Aventis Pharma Deutschland Gmbh N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
US7262220B2 (en) * 2002-07-11 2007-08-28 Sanofi-Aventis Deutschland Gmbh Urea- and urethane-substituted acylureas, process for their preparation and their use
US7208504B2 (en) 2002-10-12 2007-04-24 Sanofi-Aventis Deutschland Gmbh Bicyclic inhibitors of hormone sensitive lipase
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US20040242583A1 (en) * 2003-01-20 2004-12-02 Aventis Pharma Deutschland Gmbh Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
US7196114B2 (en) * 2003-02-17 2007-03-27 Sanofi-Aventis Deutschland Gmbh Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7173151B2 (en) * 2003-02-27 2007-02-06 Sanofi-Aventisdeutschand Gmbh Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
DE10308350B4 (de) * 2003-02-27 2006-06-01 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 1,3-Cyclohexandiol-Derivaten
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
US7094795B2 (en) 2003-02-27 2006-08-22 Sanofi-Aventis Deutschland Gmbh Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7501440B2 (en) * 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
DE10313228A1 (de) * 2003-03-25 2004-10-21 Aventis Pharma Deutschland Gmbh Synthese von 2-Chlormethyl-6-methylbenzoesäureestern
US6989462B2 (en) 2003-03-25 2006-01-24 Sanofi-Aventis Deutschland Gmbh Synthesis of 2-chloromethyl-6-methylbenzoic ester
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
EP1626711A4 (fr) * 2003-05-09 2010-10-06 Univ Pennsylvania Compositions et methodes de traitement anticancereux
WO2004099173A1 (fr) * 2003-05-12 2004-11-18 Theracarb Inc. Inhibiteurs polyvalents de la composante p des amyloides seriques
US7008957B2 (en) * 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094800B2 (en) * 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7094794B2 (en) * 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (de) * 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
BRPI0414536A (pt) * 2003-09-17 2006-11-07 Novartis Ag compostos orgánicos
EP2428516A1 (fr) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
US7470706B2 (en) * 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7402674B2 (en) * 2004-01-31 2008-07-22 Sanofi-Aventis Deutschland Gmbh, 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7498341B2 (en) * 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004005172A1 (de) * 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
EP1586573B1 (fr) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, procédé pour leur préparation, usage comme agents pharmaceutiques
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
KR20070050475A (ko) * 2004-08-11 2007-05-15 교린 세이야꾸 가부시키 가이샤 신규 환상 아미노 안식향산 유도체
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039532B4 (de) 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004040736B4 (de) * 2004-08-23 2007-01-11 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Diarylcycloalkylderivaten
US7795283B2 (en) * 2004-12-14 2010-09-14 Astrazeneca Ab Oxadiazole derivative as DGAT inhibitors
EP1671633A1 (fr) * 2004-12-17 2006-06-21 Sanofi-Aventis Deutschland GmbH Utilisation de PPAR agonistes pour traiter l'insuffisance cardiaque congestive
EP1862464A4 (fr) * 2005-03-23 2010-08-25 Kyorin Seiyaku Kk Nouveau derive acide aminophenylalcanoique cyclique
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
CA2624102A1 (fr) 2005-09-29 2007-04-12 Sanofi-Aventis Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques
JP2009520786A (ja) * 2005-12-22 2009-05-28 アストラゼネカ アクチボラグ Ｄｇａｔ阻害剤として使用するためのピリミド−［４，５−ｂ］−オキサジン
WO2007138304A1 (fr) * 2006-05-30 2007-12-06 Astrazeneca Ab Dérivés du 1,3,4-oxadiazole en tant qu'inhibiteurs de dgat1
ATE492541T1 (de) * 2006-05-30 2011-01-15 Astrazeneca Ab Substituierte 5-phenylamino-1,3,4-oxadiazol-2- ylcarbonylamino-4-phenoxycyclohexancarbonsäuren als inhibitoren von acetylcoenzym-a- diacylglycerolacyltransferase
NZ573576A (en) * 2006-06-08 2011-01-28 Astrazeneca Ab Benzimidazoles and their use for the treatment of diabetes
GB0611507D0 (en) * 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
US8115011B2 (en) * 2007-05-22 2012-02-14 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8153644B2 (en) 2007-05-22 2012-04-10 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8058299B2 (en) 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
AU2008253118B2 (en) * 2007-05-22 2013-11-21 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
WO2009024821A2 (fr) * 2007-08-17 2009-02-26 Astrazeneca Ab Composés chimiques 979
CN101381302B (zh) * 2007-09-07 2013-04-03 上海睿智化学研究有限公司 2-溴甲基-6-甲基苯甲酰氯/溴的制备方法
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
ES2535083T3 (es) 2007-12-20 2015-05-05 Astrazeneca Ab Compuestos de carbamoilo como inhibidores 190 de DGAT1
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
US8211884B2 (en) 2008-08-06 2012-07-03 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
CN102239165A (zh) 2008-12-03 2011-11-09 维尔制药公司 二酰甘油酰基转移酶抑制剂
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
WO2010077861A1 (fr) 2008-12-17 2010-07-08 Via Pharmaceuticals, Inc Inhibiteurs de la diacylglycérol acyltransférase
CN102395572A (zh) * 2008-12-19 2012-03-28 阿斯利康(瑞典)有限公司 1,3,4-噁二唑衍生物及其治疗糖尿病的用途
WO2010093601A1 (fr) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees
EP2443096A1 (fr) * 2009-06-19 2012-04-25 AstraZeneca AB Carboxamides de pyrazine utiles comme inhibiteurs de la dgat1
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
BR112012007349A2 (pt) 2009-10-02 2019-09-24 Sanofi Sa uso de composto com atividade inibidora de sglt-1/sglt-2 para produção de medicamentos para tratamento de doenças ósseas.
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2018002215A1 (fr) * 2016-06-30 2018-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de cardiomyopathies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
BR9707003A (pt) 1996-01-17 1999-07-20 Novo Nordisk As Composto processos para preparar o mesmo para tratamento ou de prevenção de doenças do sistema endócrino e para a manufatura de medicamento coposção farmacêutica e utilização de um composto
WO1997028149A1 (fr) 1996-02-02 1997-08-07 Merck & Co., Inc. Procede pour augmenter les niveaux de cholesterol hdl
CA2468374C (fr) 1996-08-30 2010-12-21 Novo-Nordisk A/S Derives de glp-1
CN1190434C (zh) 1996-12-31 2005-02-23 雷迪实验室有限公司 新的杂环化合物、其制备方法和含有它们的药物组合物及其在治疗糖尿病和相关疾病中的应用
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
BR9810592A (pt) 1997-07-16 2000-09-12 Novo Nordisk As Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
WO2000063208A1 (fr) 1999-04-16 2000-10-26 Novo Nordisk A/S Imidazoles substitues, leur preparation et utilisation
ES2287016T3 (es) 1999-04-28 2007-12-16 Sanofi-Aventis Deutschland Gmbh Derivados de diaril-acido como ligandos del receptor ppar.
SK15522001A3 (sk) * 1999-04-28 2002-06-04 Aventis Pharma Deutschland Gmbh Deriváty kyselín s tromi arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú
CA2371271A1 (fr) 1999-04-30 2000-11-09 Neurogen Corporation Derives 9h-pyrimido[4,5-b]indoles: ligands specifiques de crf1
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
US6399640B1 (en) 1999-06-18 2002-06-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
JP2003506365A (ja) 1999-07-29 2003-02-18 イーライ・リリー・アンド・カンパニー ベンゾフリルピペラジンおよびベンゾフリルホモピペラジン：セロトニンアゴニスト
PL353367A1 (en) 1999-09-01 2003-11-17 Aventis Pharma Deutschland Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
CN1430603A (zh) 2000-04-28 2003-07-16 旭化成株式会社 新型双环化合物
DE60115227T2 (de) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
EP1289526A4 (fr) 2000-05-30 2005-03-16 Merck & Co Inc Agonistes du recepteur de la melanocortine
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
PL367342A1 (en) 2005-02-21
HK1067560A1 (en) 2005-04-15
WO2003020269A1 (fr) 2003-03-13
CN1549713A (zh) 2004-11-24
BR0212158A (pt) 2004-07-13
CO5560562A2 (es) 2005-09-30
ES2278077T3 (es) 2007-08-01
HUP0401564A2 (hu) 2004-11-29
PL208515B1 (pl) 2011-05-31
US6624185B2 (en) 2003-09-23
IL160556A0 (en) 2004-07-25
OA12656A (en) 2006-06-19
HUP0401564A3 (en) 2008-05-28
TWI305724B (en) 2009-02-01
RS50889B (sr) 2010-08-31
EE05418B1 (et) 2011-06-15
BG108598A (bg) 2005-03-31
AR039063A1 (es) 2005-02-09
KR20040036924A (ko) 2004-05-03
KR100915108B1 (ko) 2009-09-03
JP2005525294A (ja) 2005-08-25
CN1255103C (zh) 2006-05-10
EE200400059A (et) 2004-04-15
CY1106378T1 (el) 2011-10-12
NZ531440A (en) 2005-10-28
HRP20040199A2 (en) 2005-04-30
MY132789A (en) 2007-10-31
PT1425014E (pt) 2007-03-30
AU2002333456B2 (en) 2008-07-17
TNSN04039A1 (en) 2006-06-01
MXPA04001850A (es) 2004-06-15
AU2002333456A2 (en) 2003-03-18
RU2330846C2 (ru) 2008-08-10
JP4436129B2 (ja) 2010-03-24
DE50208960D1 (de) 2007-01-25
EP1425014B1 (fr) 2006-12-13
RS16704A (en) 2006-12-15
EP1425014A1 (fr) 2004-06-09
CA2458210C (fr) 2011-09-20
CR7261A (es) 2008-08-04
UA76773C2 (uk) 2006-09-15
PE20030414A1 (es) 2003-06-10
DK1425014T3 (da) 2007-04-10
ATE347890T1 (de) 2007-01-15
CA2458210A1 (fr) 2003-03-13
RU2004109586A (ru) 2005-04-20
US20030144332A1 (en) 2003-07-31
IL160556A (en) 2010-05-31

Similar Documents

Publication Publication Date Title
MA27134A1 (fr) Derives diarylcycloalkyle, leur procede de preparation et leur utilisation en tant qu'activateurs des ppar
MY133732A (en) Sulfonylcarboxamide derivatives, process for their preparation and their use as medicines
MY128659A (en) Novel aminodicarboxylic acid derivatives having pharmaceutical properties
TW200635599A (en) Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
BR0014178A (pt) Derivados de ácido dicarboxìlico com propriedades farmacêuticas
NO20055892L (no) Karboksylsyrederivater
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
YU45403A (sh) Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
MY139102A (en) Substituted n-aryl heterocycles, process for their preparation and their use as medicaments
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
TW200800933A (en) Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
JO2449B1 (en) Thiosol derivatives - benziazothiazole dioxide, methods of preparation and use.
DE602005027677D1 (de) 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
HK1055117A1 (en) 8,8A-dihydro-indenoÄ11,2-dÜthiazole derivatives, amethod for their production and their use as medi caments.
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
HUP0204520A2 (en) Pharmaceutical composition containing esmolol and process for its preparation
ATE407126T1 (de) Herstellung von (s)-4-fluormethyl-dihydro-furan-2-on
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
WO2003057213A3 (fr) Composes derives de cyclohexano- et cycloheptapyrazole destines au traitement des maladies associees au recepteur 5-ht2c
NO973342L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av cerebrale degenerative sykdommer
TW200505892A (en) Substituted 3-(benzoylureido)thiophene derivatives, processes for preparing them and their use
YU22802A (sh) Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina
NO996128L (no) Nye pentaerytrittderivater, deres fremstilling og anvendelse så vel som mellomprodukter for deres syntese
CY1105308T1 (el) Θepαπεια για υπep-ουρικαιμια